Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) reported a net profit rise to SAR 61.2 million (after minority interest) in the first nine months of 2024, compared to SAR 13.2 million in the prior-year period.
Item | 9m 2023 | 9m 2024 | Change |
---|---|---|---|
Revenues | 1,320.90 | 1,295.80 | (1.9 %) |
Gross Income | 607.50 | 646.30 | 6.4 % |
Operating Income | 70.20 | 125.80 | 79.2 % |
Net Income | 13.20 | 61.20 | 363.6 % |
Average Shares | 120.00 | 120.00 | - |
EPS (Riyals) | 0.11 | 0.51 | 363.6 % |
The nine-month profit growth was triggered by a 2% year-on-year (YoY) decline in selling, general and administrative expenses (SG&A) to SAR 438 million on cost control and operating efficiency.
Other expenses fell by 93% YoY to SAR 3 million on a provision reversal. Finance costs (FCs) also declined 1% YoY to SAR 50.6 million in the nine-month period.
On the other hand, SPIMACO’s topline decreased 2% on an annual basis to SAR 1.29 billion on lower revenue from some affiliates and the suspension of some contracts.
Operating income jumped 79% YoY to SAR 125.8 million. Similarly, research and development costs (R&D) climbed 40% YoY to SAR 12.3 million.
Item | Q3 2023 | Q3 2024 | Change |
---|---|---|---|
Revenues | 381.62 | 447.00 | 17.1 % |
Gross Income | 166.30 | 216.60 | 30.2 % |
Operating Income | (19.30) | 32.20 | 266.8 % |
Net Income | (33.80) | (7.53) | 77.7 % |
Average Shares | 120.00 | 120.00 | - |
EPS (Riyals) | (0.28) | (0.06) | 77.7 % |
Item | Q2 2024 | Q3 2024 | Change |
---|---|---|---|
Revenues | 373.38 | 447.00 | 19.7 % |
Gross Income | 177.40 | 216.60 | 22.1 % |
Operating Income | 35.90 | 32.20 | (10.3 %) |
Net Income | 33.11 | (7.53) | (122.7 %) |
Average Shares | 120.00 | 120.00 | - |
EPS (Riyals) | 0.28 | (0.06) | (122.7 %) |
In the third quarter of 2024, the company cut net losses by 77.7% to SAR 7.5 million, from SAR 33.8 million in Q3 2023, thanks to a 17% YoY rise in revenue to SAR 447 million.
Gross profit jumped 30% YoY to SAR 216.6 million. The company recorded SAR 32.2 million operating income, against an operating loss of SAR 19.3 million in Q3 2023. FCs also declined by 3% YoY to SAR 23.4 million.
SPIMACO turned to losses from a net income of SAR 33.1 million in Q2 2024.
On the other hand, SG&A rose 11% YoY, with R&D costs jumping 73% annually. Zakat and tax charges also increased by 290% YoY to SAR 17 million.
SPIMACO turned to losses from a net income of SAR 33.1 million in Q2 2024. SG&A rose 34% quarter-on-quarter (QoQ). Operating income also declined to SAR 32.2 million from SAR 36 million in Q2 2024.
Total shareholders’ equity, after minority interest, saw a slight decline to SAR 1.472 billion as of Sept. 30, 2024, from SAR 1.475 billion a year earlier.
Accumulated losses came in at SAR 31 million by the end of the nine-month period, representing 2.6% of the company's capital.
Before minority interest, SPIMACO’s net income reached SAR 67.8 million, compared to SAR 17.9 million in 9M 2023.
Attached Document:
Company | Estimated | Actual | Change |
---|---|---|---|
CENOMI RETAIL | (94.00) | 19.30 | 120.5 % |
CENOMI CENTERS | 259.80 | 333.05 | 28.2 % |
DALLAH HEALTH | 125.18 | 126.16 | 0.8 % |
ALMAWARID | 25.80 | 17.10 | (33.7 %) |
MIS | 35.23 | 17.00 | (51.8 %) |
SPIMACO | 23.50 | (7.53) | (132.0 %) |
Company | Estimated | Actual | Change |
---|---|---|---|
CENOMI RETAIL | (94.00) | 19.30 | 120.5 % |
CENOMI CENTERS | 259.80 | 333.05 | 28.2 % |
DALLAH HEALTH | 125.18 | 126.16 | 0.8 % |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}